Shire (LON:SHP) Rating Reaffirmed
Bernstein now has a GBX 6000 target on the 26.22B GBP market cap company or 35.90% upside potential. In an analyst note sent to investors on Monday, 21 December, Shire (LON:SHP) shares have had their “Outperform” Rating reconfirmed by investment analysts at Bernstein.
From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 80.99. The mean of all analyst targets is GBX 88.87 with a 21.73% above today’s (GBX 4426) stock price. Shire PLC was the topic of 86 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Barclays Capital maintained shares on December 17 with “Overweight” rating. Berenberg maintained shares with “Buy” rating and GBX 6300 target share price in a report from a November 16. BNP Paribas maintained SHP stock in a recent report from December 9 with “Neutral” rating. Credit Suisse maintained the rating on November 4. Credit Suisse has a “Neutral” rating and a GBX 5400 price target on shares. Finally, JP Morgan maintained the stock with “Overweight” rating in a report issued on a December 4.
Approximately 212,708 shares of stock traded hands. Shire PLC (LON:SHP) has declined 20.22% since May 22, 2015 and is downtrending. It has underperformed by 14.41% the S&P500.
Shire plc is a biopharmaceutical company. The company has a market cap of 26.22 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 12.81 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.